(Q37825066)

23 August 2017

1 reference

title

Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders (English)

1 reference

23 August 2017

Hsin-Tzu Liu

1

1 reference

23 August 2017

Chia-Yen Chen

series ordinal

2

1 reference

23 August 2017

Hann-Chorng Kuo

series ordinal

3

1 reference

23 August 2017

language of work or name

1 reference

1 December 2010

1 reference

Journal of the Formosan Medical Association

23 August 2017

published in

1 reference

23 August 2017

volume

109

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

862-878

1 reference

Frequency‐volume charts: A tool to evaluate bladder sensation

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Is the bladder a reliable witness for predicting detrusor overactivity?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Stretch-activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Increased nerve growth factor expression triggers bladder overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Nerve growth factor mediates peripheral mechanical hypersensitivity that accompanies experimental cystitis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Changes in bladder nerve-growth factor and p75 genetic expression in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Role of urothelial nerve growth factor in human bladder function

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Immunohistochemical analysis of low-affinity nerve growth factor receptor in the human urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Histological and neurotrophic changes triggered by varying models of bladder inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Neural input regulates tissue NGF and growth of the adult rat urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Sensitisation of visceral afferents by nerve growth factor in the adult rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Convergence of sensory pathways in the development of somatic and visceral hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Cyclophosphamide induced cystitis alters neurotrophin and receptor tyrosine kinase expression in pelvic ganglia and bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Overactive bladder symptoms: do we need urodynamics?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

A PET study on brain control of micturition in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Neurological disorders of micturition and their treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Psychosocial vs. "physical" stress situations in rodents and humans: role of neurotrophins

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Time course, localization and pharmacological modulation of immediate early inducible genes, brain-derived neurotrophic factor and trkB messenger RNAs in the rat brain following photochemical stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Nerve growth factor and transforming growth factor-beta serum levels in acute stroke patients. Possible involvement of neurotrophins in cerebrovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Increased levels of truncated nerve growth factor receptor in urine of mildly demented patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Response of bladder smooth muscle cells to obstruction: signal transduction and the role of mechanosensors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Voiding dysfunction following transurethral resection of the prostate: symptoms and urodynamic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Changes in galanin immunoreactivity in rat lumbosacral spinal cord and dorsal root ganglia after spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Genetic manipulation of intraspinal plasticity after spinal cord injury alters the severity of autonomic dysreflexia

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

The impact on health‐related quality of life of stress, urge and mixed urinary incontinence

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Prevalence of persistent and de novo overactive bladder symptoms after the tension-free vaginal tape

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Five-year outcomes of the tension-free vaginal tape procedure for treatment of female stress urinary incontinence.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

The predictive value of preoperative pressure-flow studies in the resolution of detrusor overactivity and overactive bladder after tension-free vaginal tape insertion.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Videourodynamic evaluation of urge syndrome following pubovaginal sling procedure for stress urinary incontinence in women

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Defining overactive bladder as hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Management of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960133-7

7 January 2021

10.1016/S0929-6646(10)60133-7

Identifiers

DOI

1 reference

23 August 2017

1 reference